Close Menu

Well, knock GTO over with a feather: we never thought we'd see the day that "RNA interference" made it into a Wall Street Journal headline. This article reports on recent results from Alnylam Pharmaceuticals' human trial for its RNAi-based drug for respiratory syncytial virus. The story quotes Alnylam CEO John Maraganore as saying, "This is really the first moonwalk for RNAi therapeutics." Michael Jackson would be so proud.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.